Answers are grounded in this paper and cite their sources.
The PI3K pathway is often aberrantly activated in estrogen receptor positive (ER(+)) breast cancer and therapies combining PI3K inhibitors and antiestrogens are under clinical development. Given that many PI3K inhibitors have substantial toxicities with continuous dosing and that alternate dosing schedules are equally active, further clinical exploration is warranted. Clin Cancer Res; 22(9); 2099-101.
No takes yet. Share an insight, caveat, or question.
Toska et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: